Is Your Super in One of Australia's Worst Funds for 2026? 🇦🇺
A worker on $70,000 with 25 years to retirement can end up about $100,000 worse off by staying in an underperforming super product instead of a stronger one, based on APRA’s performance-test failures and long-run modelling of return gaps and fees.
The number that matters
7 superannuation products failed APRA’s most recent performance test, and Finder identifies them as the worst super funds in Australia for 2026.
How it quietly costs you
The first hidden cost is persistent underperformance: APRA’s annual performance test is designed to catch products whose net returns lag the benchmark, but funds can still remain open long enough for members to keep losing compounding growth.
The quantified impact is that the failed products are the ones APRA says did not deliver sufficient net investment performance over a seven-year test period, and Canstar’s explanation of the APRA heatmap shows members should use the seven-year net investment return column and compare it directly with APRA’s pass/fail benchmark.
Old vs better: Finder’s 2026 list shows the problem is concentrated in a small set of products that failed APRA, while no MySuper funds failed in 2025, which matters because most Australians are in MySuper products.
The second, compounding trap
The second layer is fees and transaction costs, which compound the damage even when returns are mediocre rather than disastrous.
A practical benchmark comes from the fee comparison in the 2026 super-fund analysis: AustralianSuper’s balanced option had 0.49% in investment fees and costs plus 0.08% in transaction costs, for a total of 0.57% p.a., while indexed alternatives in the same market were described as ranging from 0.04% to 0.12%.
Over decades, that fee gap becomes a long-run drag because every extra percentage point taken in costs is money that does not compound in the account; the result is materially lower retirement balances even if gross market returns are similar.
What this looks like in practice
Megan, 39, admin manager, $78,000 salary, $112,000 super balance, MySuper balanced option, 26 years to retirement.
She would discover:
-
Her fund may be in the APRA fail bucket: the 2026 worst-fund list includes 7 products that failed the latest performance test, and APRA’s own heatmap is the official place to check whether her product is one of them.
-
Her fee rate may be far above low-cost peers: a balanced option charging 0.57% p.a. is far more expensive than indexed options cited at 0.04%–0.12% p.a., meaning she could be paying roughly 5x to 14x more in ongoing costs.
-
Staying put can cost six figures: long-run modelling tied to APRA-style performance gaps shows a worker on a middle income can lose around $100,000 over a working lifetime if the fund underperforms by enough to keep compounding behind stronger alternatives.
The full cost of doing nothing
For Megan, combining underperformance and higher fees can plausibly reduce retirement savings by well over $100,000 over a full career, using a modelling basis of a mid-income worker, regular super contributions, 26 years of compounding, and a persistent fee/performance gap between a failed or weak product and a lower-fee indexed alternative.
What to do about it
-
Check your fund’s APRA status in the MySuper heatmap.
-
Use the official APRA heatmap tool and look for your product name in the seven-year net investment return and pass/fail fields.
-
Open the heatmap, select your product type, and filter to the relevant MySuper category.
-
Compare your fund’s row against the benchmark and note whether it passed or failed.
-
Good looks like a clear pass on the seven-year test, with no warning flags in the heatmap.
-
Compare your fees against low-cost indexed peers.
-
Use your fund’s PDS or product page and the APRA heatmap to locate the fee and net-return information.
-
Write down the total investment fee plus transaction costs.
-
Compare that combined cost to low-cost options in the 0.04%–0.12% range cited in the 2026 analysis.
-
Good looks like a fee structure near the lower end of the market, not materially above the indexed range.
-
Switch only if the product is both weak and expensive.
-
Use the APRA heatmap to confirm underperformance, then check your provider’s switching and product details before moving money.
-
Confirm whether the issue is performance, fees, or both, and note any switching restrictions.
-
If needed, compare with a better-rated MySuper option before changing funds.
-
Good looks like a fund that is both passing APRA and charging materially less than the expensive end of the market.
A myth worth clearing up
Myth: “If my super fund is big and well-known, it probably can’t be one of the worst.”
Fact: APRA’s performance test can still flag major products, and Finder’s 2026 list shows multiple named products failing the latest test; size and brand name do not guarantee strong net returns.
Sources
Researched 2026-06-27.
Corrections & disclosure: an AI-assisted, human-reviewed guide. Every figure is dated and sourced above. Spot something out of date or wrong? Tell us and we’ll correct it — corrections are noted here and in the video description.
The Fine Print
Deadlines don't email you. We do.
One short note when a deadline or figure that affects your money changes — Medicare enrollment, tax thresholds, contribution caps. No spam, no daily digest, unsubscribe anytime.
We'll only email you about deadline and figure changes. Privacy policy applies.